Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | IKBKB | O14920 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.36 |
| ▸ | CHUK | O15111 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | PAICS | P22234 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23830994 | 0.89 | CHRNB2 (0.46) | SLC6A2HTR1A | |
| SCHEMBL23830992 | 0.89 | CHRNB2 (0.46) | SLC6A2HTR1A | |
| Methane SCHEMBL29003897 | 0.88 | CHRNB2 (0.45) | SLC6A2HTR1A | |
| SCHEMBL27571710 | 0.81 | HRH1 (0.43) | HRH1SLC6A2HTR1ASLC6A3IKBKB | |
| SCHEMBL29003859 | 0.81 | HRH1 (0.43) | HRH1SLC6A2HTR1ASLC6A3IKBKB | |
| Hydrochloric Acid SCHEMBL4107967 | 0.81 | IRAK4 (0.43) | HRH1TDO2SLC6A2HTR1ASLC6A3 | |
| SCHEMBL9900853 | 0.81 | SLC6A2 (0.41) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4711714 | 0.80 | HRH1 (0.42) | HRH1SLC6A2HTR1ASLC6A3IKBKB | |
| Hydrochloric Acid SCHEMBL2776816 | 0.80 | HTR2C (0.42) | HRH1SLC6A2HTR1ASLC6A3IKBKB | |
| Hydrochloric Acid SCHEMBL4114449 | 0.79 | SLC6A2 (0.40) | SLC6A2HTR1ASLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108456204-B | Benzothiazine derivative, and preparation method and application thereof | 四川大学 | 2023-05-26 | — | — | CN | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | HRH1 2214/4885TDO2 413/4885SLC6A2 3817/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | HRH1 2214/4885TDO2 413/4885SLC6A2 3817/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | HRH1 1395/4885TDO2 798/4885SLC6A2 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.